Halozyme Therapeutics
HALO
#1870
Rank
HK$81.63 B
Marketcap
HK$716.01
Share price
-1.82%
Change (1 day)
30.90%
Change (1 year)

P/S ratio for Halozyme Therapeutics (HALO)

P/S ratio as of November 2026 (TTM): 6.37

According to Halozyme Therapeutics's latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 73.8. At the end of 2026 the company had a P/S ratio of 5.34.

P/S ratio history for Halozyme Therapeutics from 2005 to 2026

PS ratio at the end of each year

Year P/S ratio Change
20265.34-9.73%
20255.92-1.84%
20246.032.44%
20235.89-49.48%
202211.7-8.73%
202112.8-40.81%
202021.674.46%
201912.4-11.3%
201813.953.06%
20179.114.45%
20168.72-46.96%
201516.42.11%
201416.1-48.6%
201331.375.34%
201217.91.63%
201117.6-69.93%
201058.548.53%
200939.4-24.36%
200852.0-64.3%
2007146-74.13%
2006564-33.42%
2005847

P/S ratio for similar companies or competitors

Company P/S ratio P/S ratio differencediff. Country
Johnson & Johnson
JNJ
6.59 3.50%๐Ÿ‡บ๐Ÿ‡ธ USA
Pfizer
PFE
2.47-61.17%๐Ÿ‡บ๐Ÿ‡ธ USA
Eli Lilly
LLY
13.9 118.97%๐Ÿ‡บ๐Ÿ‡ธ USA
Sanofi
SNY
1.92-69.89%๐Ÿ‡ซ๐Ÿ‡ท France
Baxter
BAX
1.14-82.15%๐Ÿ‡บ๐Ÿ‡ธ USA
MannKind Corp
MNKD
3.21-49.63%๐Ÿ‡บ๐Ÿ‡ธ USA